MEDIUM confidence: 100% data completeness, but the composite (50) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Low explanatory power (R² 0.02) — the factor model explains little of this stock's return variation, so these exposures are noisy. Interpret with caution.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Avg target $239 (last qtr, 18 analysts) → $261 (last mo, 8) (+9.4%).
Buy-rated share 55% → 64% over ~3 months (+9pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $2.94 | $3.60 | +22.4% |
| Apr 2026 | $3.05 | $3.57 | +17.0% |
| Feb 2026 | $1.63 | $1.99 | +22.1% |
| Oct 2025 | $3.88 | $4.81 | +24.0% |
| Jul 2025 | $3.90 | $5.47 | +40.3% |
| May 2025 | $2.90 | $3.02 | +4.1% |
| Feb 2025 | $3.43 | $3.44 | +0.3% |
| Oct 2024 | $3.77 | $4.08 | +8.2% |
Net insider -$240K over 180 days (0 open-market buys, 2 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $11.0B— | $10.2B-7.4% | $9.8B-3.3% | $9.7B-1.6% | $9.8B+1.4% |
| EPS (dil.) | $10.40— | $20.87+100.7% | $7.97-61.8% | $11.19+40.4% | $8.83-21.1% |
| Free Cash Flow | $3.4B— | $1.1B-66.2% | $1.2B+8.0% | $2.5B+103.6% | $2.1B-18.5% |
| Gross Margin | 80.8% | 77.6%-3.2pp | 74.2%-3.4pp | 76.1%+1.9pp | 70.5%-5.7pp |
| Operating Margin | 25.4% | 28.4%+3.0pp | 21.3%-7.1pp | 25.7%+4.4pp | 19.1%-6.6pp |
| Net Margin | 14.2% | 29.9%+15.8pp | 11.8%-18.1pp | 16.9%+5.1pp | 13.2%-3.7pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 2.1%/yr (revenue basis).
Base free cash flow $1.9B (avg FY2023–FY2025; latest year $2.1B) · equity value $31.1B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 50 for Biogen Inc. suggests a neutral outlook, with the stock's strengths and weaknesses balancing out. The company scores high on momentum, with a 12-month return of 63.0%, and exhibits strong profitability, with a gross margin of 67.7%. However, its growth score is dragged down by negative EPS and free cash flow growth, and it trades at a premium, with a P/E of 37.0. The long-term and short-term scores are relatively aligned, indicating a consistent view of the stock's prospects.